A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose

Yoshimi Tsuda, Christopher J. Parkins, Patrizia Caposio, Friederike Feldmann, Sara Botto, Susan Ball, Ilhem Messaoudi, Luka Cicin-Sain, Heinz Feldmann, Michael A. Jarvis

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

Ebola virus (Zaire ebolavirus; EBOV) is a highly lethal hemorrhagic disease virus that most recently was responsible for two independent 2014 outbreaks in multiple countries in Western Africa, and the Democratic Republic of the Congo, respectively. Herein, we show that a cytomegalovirus (CMV)-based vaccine provides durable protective immunity from Ebola virus following a single vaccine dose. This study has implications for human vaccination against ebolaviruses, as well as for development of a 'disseminating' vaccine to target these viruses in wild African great apes.

Original languageEnglish (US)
Pages (from-to)2261-2266
Number of pages6
JournalVaccine
Volume33
Issue number19
DOIs
StatePublished - Jan 1 2015

Keywords

  • Cytomegalovirus
  • Disseminating
  • Durable
  • Ebola
  • Ebolavirus
  • Great apes
  • Mouse
  • Protection
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose'. Together they form a unique fingerprint.

  • Cite this

    Tsuda, Y., Parkins, C. J., Caposio, P., Feldmann, F., Botto, S., Ball, S., Messaoudi, I., Cicin-Sain, L., Feldmann, H., & Jarvis, M. A. (2015). A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose. Vaccine, 33(19), 2261-2266. https://doi.org/10.1016/j.vaccine.2015.03.029